(Total Views: 435)
Posted On: 11/27/2019 2:26:28 PM
Post# of 72445
An internal pathway to raise money for B-OM P3 is highly unlikely IMHO. 100M shares at 6 cents per share equals to $6M. Leo said B-ABSSSI P3 would cost $30M. Let’s say B-OM P3
costs $18M. That’ll be 300M additional shares in dilution. $18M is my conservative estimate based on how much B-OM P2 cost, but I know I’ll be called a basher or get a thumbs down again for my opinion.
Both IPIX and Gelera finished the OM P2 trial in 2017. Gelera received BTD and raised $150M in 2018. Their P3 trial is underway in 2019. Leo claimed B-OM is superior than GC4419, which I agree because oral rinse is better than IV. But why hasn’t Leo been able to find a partner? He started to mention “discussions with potential business partners” in 2017.
costs $18M. That’ll be 300M additional shares in dilution. $18M is my conservative estimate based on how much B-OM P2 cost, but I know I’ll be called a basher or get a thumbs down again for my opinion.
Both IPIX and Gelera finished the OM P2 trial in 2017. Gelera received BTD and raised $150M in 2018. Their P3 trial is underway in 2019. Leo claimed B-OM is superior than GC4419, which I agree because oral rinse is better than IV. But why hasn’t Leo been able to find a partner? He started to mention “discussions with potential business partners” in 2017.
(4)
(0)
